Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 9/20 | 1.00 |
| ▸ | F10 | P00742 | 9/20 | 1.00 |
| ▸ | PLG | P00747 | 9/20 | 1.00 |
| ▸ | PLAU | P00749 | 9/20 | 1.00 |
| ▸ | HPN | P05981 | 9/20 | 1.00 |
| ▸ | PLAT | P00750 | 7/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 3/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 3/20 | 1.00 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.70 |
| ▸ | F7 | P08709 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18817939 | 0.85 | HPN (1.00) | F2PRSS1F10PLGPLAU | |
| SCHEMBL23752374 | 0.84 | F2 (0.73) | F2PRSS1F10PLGPLAU | |
| SCHEMBL1325070 | 0.83 | F2 (1.00) | F2PRSS1F10PLGPLAU | |
| SCHEMBL29682938 | 0.83 | F2 (1.00) | F2PRSS1F10PLGPLAU | |
| SCHEMBL18845628 | 0.82 | F2 (1.00) | F2PRSS1F10PLGPLAU | |
| SCHEMBL11786839 | 0.81 | F2 (0.68) | F2PRSS1F10PLGPLAU | |
| SCHEMBL13208176 | 0.81 | F2 (1.00) | F2PRSS1F10PLGPLAU | |
| SCHEMBL18817916 | 0.79 | HPN (1.00) | F2PRSS1F10PLGPLAU | |
| SCHEMBL18817953 | 0.79 | HPN (1.00) | F2PRSS1F10PLGPLAU | |
| SCHEMBL18817912 | 0.78 | HPN (1.00) | F2PRSS1F10PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-10155753-B2 | 4-substituted-2-(5-substituted-1H-indol-2-yl)phenol derivatives, methods for preparing the phenol derivatives and pharmaceutical compositions for inhibiting cell proliferation and migration including the phenol derivatives | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2018-12-18 | — | — | US | disclosed |
| US-20170129879-A1 | 4-SUBSTITUTED-2-(5-SUBSTITUTED-1H-INDOL-2-YL)PHENOL DERIVATIVES, METHODS FOR PREPARING THE PHENOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION AND MIGRATION INCLUDING THE PHENOL DERIVATIVES | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-05-11 | — | — | US | disclosed |
| US-20170129879-A1 | 4-SUBSTITUTED-2-(5-SUBSTITUTED-1H-INDOL-2-YL)PHENOL DERIVATIVES, METHODS FOR PREPARING THE PHENOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION AND MIGRATION INCLUDING THE PHENOL DERIVATIVES | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-05-11 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155753-B2 | 4-substituted-2-(5-substituted-1H-indol-2-yl)phenol derivatives, methods for preparing the phenol derivatives and pharmaceutical compositions for inhibiting cell proliferation and migration including the phenol derivatives | MKI67, CCNI, CDK4 | F2 3001/4885PRSS1 3185/4885F10 2970/4885 |
| US-20170129879-A1 | 4-SUBSTITUTED-2-(5-SUBSTITUTED-1H-INDOL-2-YL)PHENOL DERIVATIVES, METHODS FOR PREPARING THE PHENOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION AND MIGRATION INCLUDING THE PHENOL DERIVATIVES | MKI67, CCNI, CDK4 | F2 3001/4885PRSS1 3185/4885F10 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.